A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Completed · Phase 3 · Has a placebo group

Conditions studied: Small Cell Lung Carcinoma

In brief

This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.

Key facts

Study ID

NCT02763579

Run by

Hoffmann-La Roche

People needed

503

Starts

2016-06-07

Expected to finish

2022-07-07

Last updated by the study team

2023-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)
• No prior systemic treatment for ES-SCLC
• Eastern Cooperative Oncology Group performance status of 0 or 1
• Measurable disease, as defined by RECIST v1.1
• Adequate hematologic and end organ function
• Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC

You may not qualify if…

• Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation
• Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
• Pregnant or lactating women
• History of autoimmune disease
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
• Positive test result for human immunodeficiency virus (HIV)
• Active hepatitis B or hepatitis C
• Severe infections at the time of randomization
• Significant cardiovascular disease
• Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti-PD-L1 therapeutic antibody
• History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation.

Where it is running

• Florida Hospital — Orlando, Florida, United States
• Florida Cancer Specialists. — St. Petersburg, Florida, United States
• Northwest Georgia Oncology Centers PC - Marietta — Marietta, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Illinois Cancer Care — Peoria, Illinois, United States
• Cancer Treatment Centers of America - Midwestern Regional Medical Center — Zion, Illinois, United States
• Louisville Oncology — Louisville, Kentucky, United States
• New England Cancer Specialists — Scarborough, Maine, United States
• Weinberg CA Inst Franklin Sq — Baltimore, Maryland, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Comprehensive Cancer Centers of Nevada - Eastern Avenue — Las Vegas, Nevada, United States
• The Valley Hospital — Paramus, New Jersey, United States
• Broome Oncology - Binghamton — Binghamton, New York, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• Tennessee Oncology Chattanooga — Chattanooga, Tennessee, United States
• Tennessee Oncology PLLC - Nashville (20th Ave) — Nashville, Tennessee, United States
• Vanderbilt Medical Center — Nashville, Tennessee, United States
• Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
• Blue Ridge Cancer Care — Roanoke, Virginia, United States
• Northwest Medical Specialties — Tacoma, Washington, United States
• University of Wisconsin — Madison, Wisconsin, United States
• Chris O'Brien Lifehouse — Camperdown, New South Wales, Australia
• The Prince Charles Hospital; Oncology Dept. — Chermside, Queensland, Australia
• Royal Melbourne Hospital; Hematology and Medical Oncology — Parkville, Victoria, Australia
• Florida Cancer Specialists - Fort Myers (Broadway) — Fort Myers, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.